Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Positive efficacy and safety results reported for IDEC-Y2B8/Rituxan in NHL

Oct. 29, 1998

Japanese patent allowed for Maxamine technology

Oct. 22, 1998

Coulter announces positive investigational phase III results from Bexxar in NHL

Oct. 22, 1998

Endorex adds second site to phase II ImmTher trial

Oct. 16, 1998

Rituximab now available in Germany

Oct. 14, 1998

Antibody-based cancer product from AltaRex heading for phase I testing

Oct. 14, 1998

Coulter initiates expanded access program for Bexxar

Oct. 8, 1998

Patent issued for Neoprobe's RIGS/ACT anticancer technology

Oct. 7, 1998

Genentech's Herceptin given FDA approval

Sep. 28, 1998

Enzon's PEG-Intron A advances to phase III trials for malignant melanoma

Sep. 24, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.